Close Menu

optical mapping

The firm is offering approximately 13.8 million shares and the same number of warrants to purchase shares, which will be sold together.

The San Diego-based genome mapping company attributed the drop in revenues to fewer international sales of its Saphyr platform.

The company reported $1.9 million in Q1 revenues amid a widened net loss of $7.9 million that was driven by increased operating expenses.

The company also entered into two separate financing agreements totaling $41.5 million with Innovatus Life Sciences Lending Fund, East West Bank, and Aspire Capital.

A team led by researchers at the University of California, San Francisco generated optical genome maps for 154 individuals from more than two dozen populations.

Several groups are comparing Bionano with standard cytogenetic assays like karyotyping, FISH, or array CGH for blood cancer or genetic disease testing.

With Hi-C mapping, FISH imaging insights, and other approaches, researchers identified genome organization plasticity and between-allele variability.

Circulomics, Bionano, Sage Science, RevoluGen, and others have been developing methods for extracting DNA hundreds of kilobases and up to megabases in length.

With long-read sequencing, mapping, and other approaches, researchers assembled a high-quality genome for Aedes aegypti, a notorious infectious disease vector.

Fresh off its August IPO, the company reported $2.8 million in revenue for the quarter, up from $2.7 million a year ago.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.